Bocxman, Come on! You have not given me any reasons why Moro only got a pittance of up front money after an entire year of dilligence by ABT. Also, please tell us why no other pharma has made additional licensings of RECAF.
If you cannot come up with any valid reasons, I suggest you put the dunce cap on yourself.
As for Abbott and cancer tests, Abbott/Europroteome are codeveloping breast cancer diagnostic tests.
Abbott has the ARCHITECT CA 125 II and Architect CA 15–3 Assays for ovarian and breast cancers.
The deal with Vysis PathVysion test provides a DNA-based assessment of HER-2 gene amplification for breast cancer.
They have a colon cancer marker in HUMIRA(R) that is in trials.
And of course they have the PSA tests.
The above is certainly not a complete list of their cancer tests in exploration, development or currently available but it does show they have a great interest in any possible marker out there. If you came up with a cancer marker yourself, I'm sure you could interest Abbott if you gave them some decent research that it might be valid.
BTW, care to disclose how much money you have made trading BOCX on peaks over the past couple of years?
News 
Market Data 
Discover 
